Clinical Trial: Safety and Tolerability of NCP-IL-22BP mRNA in Advanced Solid Tumors

U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07562815) titled 'Safety and Tolerability of NCP-IL-22BP mRNA in Advanced Solid Tumors' on April 24.

Brief Summary: This is a phase I, open-label, single-arm, single-center, dose-escalation study to evaluate the safety, tolerability, and preliminary anti-tumor activity of NCP-IL-22BP mRNA, a non-cationic peptide-delivered mRNA encoding interleukin-22 binding protein (IL-22BP), administered by intratumoral injection in patients with advanced malignant solid tumors who have failed second-line therapy. The study employs a classical "3+3" dose-escalation design with three dose levels (25 μg, 50 μg, and 100 μg mRNA). Each subject will receive...